Perceptions and Beliefs Regarding NSAIDs in the Asia-Pacific Region
Authors Ho KY
Received 31 August 2019
Accepted for publication 12 February 2020
Published 21 February 2020 Volume 2020:13 Pages 437—446
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Michael Schatman
The Pain Clinic, Mount Alvernia Hospital, Singapore
Correspondence: Kok-Yuen Ho
The Pain Clinic, Mount Alvernia Hospital, 820 Thomson Road – 07-59, 574623, Singapore
Tel/Fax +65 6 254 5447
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in the treatment of pain and inflammation. However, chronic NSAID use may result in gastrointestinal (GI), cardiovascular (CV), renal or other safety concerns, especially in high-risk populations. The aim of this review is to systematically identify relevant literature and to organize available evidence for perceptions or beliefs of physicians and patients about the safety and efficacy of NSAIDs.
Methods: A systematic literature search was conducted in MEDLINE® (through PubMed®), Embase® (through Ovid®), and the Cochrane Library. Additional unstructured searches were conducted using Google Scholar™ and Google. The scope of this study did not include grey literature searches or handpicking of cross references. This systematic analysis was conducted with a special interest in studies conducted in the Asia-Pacific (APAC) region and information related to the COX-2 (cyclooxygenase-2) selective inhibitors.
Results: Out of a total of 2822 studies retrieved from different databases (PubMed®, Cochrane, Google Scholar™ and Embase®), 99 (3.5%) met the inclusion criteria. Further, out of these 99 studies, 23 APAC region studies were analyzed. The common perceptions were related to GI, CV, renal and respiratory safety, efficacy and COX-2 inhibitors.
Conclusion: Overall, the level of awareness among patients regarding NSAIDs was observed to be considerably poor. Moreover, risk stratification by physicians must be practiced in order to decrease the incidence of adverse events.
Keywords: cardiovascular, COX-2 inhibitors, efficacy, gastrointestinal, renal, respiratory
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]